

IRELAND: MEDICINAL PRODUCTS FOR THE BLOOD, BLOOD-FORMING ORGANS AND THE CARDIOVASCULAR SYSTEM

FIBRINOGEN CONCENTRATE USED FOR CONGENITAL AFIBRINOGENAEMIA AND DYSFIBRINOGENAEMIA

Contract or concession award notice – standard regime

1 Buyer

1.1 Buyer

Official name: Irish Blood Transfusion Service

Legal type of the buyer: Body governed by public law

Activity of the contracting authority: Health

2 Procedure

2.1 Procedure

Title: Fibrinogen concentrate used for congenital afibrinogenemia and dysfibrinogenemia

Description: Human fibrinogen concentrate is used for congenital afibrinogenemia and dysfibrinogenemia states for treatment of bleeding complications. It is also used in acquired hypofibrinogenemia conditions such as massive haemorrhage, acquired coagulopathy, liver disease with bleeding and in obstetric haemorrhage. The product should be licensed for these clinical indications and approved by the HPRA. Fibrinogen, in presence of thrombin, activates FVIII and calcium, which is necessary to convert fibrinogen into stable three-dimensional fibrin coagula. The IBTS is responsible for the distribution of fibrinogen to users nationwide. IBTS must therefore have a sufficient stock and a stable supply of fibrinogen concentrates to meet patient needs.

Procedure identifier: 1fec4524-8652-4cee-9b84-75ba84109e8d

Type of procedure: Open

The procedure is accelerated: no

2.1.1 Purpose

Main nature of the contract: Supplies

Main classification (cpv): 33620000 Medicinal products for the blood, blood-forming organs and the cardiovascular system

Additional classification (cpv): 33621000 Medicinal products for the blood and blood-forming organs

Additional classification (cpv): 33622000 Medicinal products for the cardiovascular system

2.1.4 General information

Legal basis:

Directive 2014/24/EU

5 Lot

5.1 Lot technical ID: LOT-0001

Title: Fibrinogen concentrate used for congenital afibrinogenemia and dysfibrinogenemia

Description: Human fibrinogen concentrate is used for congenital afibrinogenemia and dysfibrinogenemia states for treatment of bleeding complications. It is also used in acquired hypofibrinogenemia conditions such as massive haemorrhage, acquired coagulopathy, liver disease with bleeding and in obstetric haemorrhage. The product should be licensed for these clinical indications and approved by the HPRA. Fibrinogen, in presence of thrombin, activates

FVIII and calcium, which is necessary to convert fibrinogen into stable three-dimensional fibrin coagula. The IBTS is responsible for the distribution of fibrinogen to users nationwide. IBTS must therefore have a sufficient stock and a stable supply of fibrinogen concentrates to meet patient needs.

Internal identifier: 0

5.1.1 Purpose

Main nature of the contract: Supplies

Main classification (cpv): 33620000 Medicinal products for the blood, blood-forming organs and the cardiovascular system

Additional classification (cpv): 33621000 Medicinal products for the blood and blood-forming organs

Additional classification (cpv): 33622000 Medicinal products for the cardiovascular system

5.1.6 General information

Procurement Project not financed with EU Funds.

The procurement is covered by the Government Procurement Agreement (GPA)

5.1.10 Award criteria

Criterion:

Type: Quality

Description: Quality

Description of the method to be used if weighting cannot be expressed by criteria: 0000

5.1.15 Techniques

Framework agreement:

No framework agreement

Information about the dynamic purchasing system:

No dynamic purchase system

5.1.16 Further information, mediation and review

Review organisation: The High Court of Ireland

Organisation providing offline access to the procurement documents: Irish Blood Transfusion Service

TED eSender: European Dynamics S.A.

6 Results

Value of all contracts awarded in this notice: 0 EUR

6.1 Result lot Identifier: LOT-0001

At least one winner was chosen.

6.1.2 Information about winners

Winner:

Official name: Octapharma AG

Tender:

Tender identifier: 000019131

Identifier of lot or group of lots: LOT-0001

Subcontracting value is known: no

Subcontracting percentage is known: no

Contract information:

Identifier of the contract: 393663

Date on which the winner was chosen: 2024-01-01Z

Date of the conclusion of the contract: 2024-01-02Z
The contract is awarded within a framework agreement: no

6.1.4 Statistical information

Received tenders or requests to participate:
Type of received submissions: Tenders
Number of tenders or requests to participate received: 2
Range of tenders:
Value of the lowest admissible tender: 0 EUR
Value of the highest admissible tender: 0 EUR

8 Organisations

8.1 ORG-0001

Official name: Irish Blood Transfusion Service
Registration number: 0079525H
Town: Dublin
Country: Ireland
Email: brian.boland@ibts.ie
Telephone: 0858310894
Buyer profile: <https://www.giveblood.ie>
Roles of this organisation:
Buyer
Organisation providing offline access to the procurement documents

8.1 ORG-0002

Official name: Octapharma AG
Registration number: CHE-108.025.582
Postal address: Seidenstrasse 2,
Town: Lachen
Postcode: CH-8853
Country: Switzerland
Email: andy.walsh@octapharma.com
Telephone: 07885995899
Fax: 01618373799
Internet address: www.octapharma.com
Roles of this organisation:
Tenderer
Winner of these lots: LOT-0001

8.1 ORG-0003

Official name: The High Court of Ireland
Registration number: The High Court of Ireland
Department: The High Court of Ireland
Postal address: Four Courts, Inns Quay, Dublin 7
Town: Dublin
Postcode: D07 WDX8
Country: Ireland
Email: HighCourtCentralOffice@courts.ie

Telephone: +353 1 8886000

Roles of this organisation:

Review organisation

8.1 ORG-0004

Official name: European Dynamics S.A.

Registration number: 002024901000

Department: European Dynamics S.A.

Town: Athens

Country: Greece

Email: eproc-esender@eurodyn.com

Telephone: +30 2108094500

Roles of this organisation:

TED eSender

11 Notice information

11.1 Notice information

Notice identifier/version: ff380fe3-8bb8-430f-86f8-ac3d2221e150 - 01

Form type: Result

Notice type: Contract or concession award notice – standard regime

Notice dispatch date: 2024-03-28Z 10:43:47Z

Languages in which this notice is officially available: English

11.2 Publication information